دورية أكاديمية
Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe.
| العنوان: | Trends in the Prevalence of Methylchloroisothiazolinone/Methylisothiazolinone Contact Allergy in North America and Europe. |
|---|---|
| المؤلفون: | Reeder MJ; Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison., Warshaw E; Department of Dermatology, Park Nicollet Health Services, Minneapolis, Minnesota.; Department of Dermatology, University of Minnesota, Minneapolis.; Department of Dermatology, Minneapolis Veterans Affairs Medical Center, Minneapolis, Minnesota., Aravamuthan S; Department of Dermatology, University of Wisconsin School of Medicine and Public Health, Madison., Belsito DV; Department of Dermatology, Columbia University Irving Medical Center, New York, New York., Geier J; Information Network of Departments of Dermatology, Institute at the University Medical Center Göttingen, Göttingen, Germany., Wilkinson M; Department of Dermatology, Leeds Teaching Hospitals National Health Service Trust, Chapel Allerton Hospital, Leeds, England., Atwater AR; Department of Dermatology, Duke University Medical Center, Durham, North Carolina., White IR; St John's Institute of Dermatology, Guy's Hospital, London, England., Silverberg JI; Department of Dermatology, George Washington University School of Medicine, Washington, DC.; Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois., Taylor JS; Department of Dermatology, Cleveland Clinic, Cleveland, Ohio., Fowler JF Jr; Division of Dermatology, University of Louisville, Louisville, Kentucky., Maibach HI; Department of Dermatology, University of California, San Francisco., DeKoven JG; Division of Dermatology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada., Buhl T; Department of Dermatology, Venereology and Allergology, Georg August University, Göttingen, Germany., Botto N; Department of Dermatology, University of California, San Francisco., Giménez-Arnau AM; Department of Dermatology, Hospital del Mar, Universitat Pompeu Fabra, Barcelona, Spain., Gallo R; Clinica Dermatologica, IRCCS-AOU San Martino-IST and Department of Health Sciences, University of Genoa, Genoa, Italy., Mowad C; Division of Dermatology, Geisinger Medical Center, Danville, Pennsylvania., Lang CCV; Department of Dermatology, University Hospital of Zurich, Zurich, Switzerland., DeLeo VA; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles., Johnston G; Department of Dermatology, Leicester Royal Infirmary, Leicester, England., Pratt MD; Division of Dermatology, University of Ottawa, Ottawa, Ontario, Canada., Brockow K; Department of Dermatology and Allergology Biederstein, Faculty of Medicine, Technical University Munich, Munich, Germany., Adler BL; Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles., Houle MC; Division of Dermatology, Centre Hospitalier Universitaire de Quebec, Laval University, Quebec, Quebec, Canada., Dickel H; Department of Dermatology, Venereology and Allergology, St Josef Hospital, University Medical Center, Ruhr University Bochum, Bochum, Germany., Schuttelaar MLA; Department of Dermatology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands., Yu J; Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Spiewak R; Department of Experimental Dermatology and Cosmetology, Jagiellonian University Medical College, Krakow, Poland., Dunnick C; Department of Dermatology, University of Colorado, Denver., Filon FL; Department of Public Health, Occupational Medicine, University of Trieste, Trieste, Italy., Valiukeviciene S; Department of Skin and Venereal Diseases, Lithuanian University of Health Sciences, Kaunas, Lithuania., Uter W; Department of Medical Informatics, Biometry and Epidemiology, University of Erlangen/Nürnberg, Erlangen, Germany. |
| المصدر: | JAMA dermatology [JAMA Dermatol] 2023 Mar 01; Vol. 159 (3), pp. 267-274. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589530 Publication Model: Print Cited Medium: Internet ISSN: 2168-6084 (Electronic) Linking ISSN: 21686068 NLM ISO Abbreviation: JAMA Dermatol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Chicago, IL : American Medical Association, [2013]- |
| مواضيع طبية MeSH: | Dermatitis, Allergic Contact*/diagnosis , Dermatitis, Allergic Contact*/epidemiology , Dermatitis, Allergic Contact*/etiology, Humans ; Prevalence ; Retrospective Studies ; North America/epidemiology ; Europe/epidemiology ; Patch Tests/methods |
| مستخلص: | Importance: The common use of isothiazolinones as preservatives is a global cause of allergic contact dermatitis. Differences in allowable concentrations of methylisothiazolinone (MI) exist in Europe, Canada, and the US. Objective: To compare the prevalence of positive patch test reactions to the methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) combination and MI alone in North America and Europe from 2009 to 2018. Design, Setting, and Participants: This retrospective analysis of North American Contact Dermatitis Group, European Surveillance System on Contact Allergies (ESSCA), and the Information Network of Departments of Dermatology (IVDK) databases included data from patients presenting for patch testing at referral patch test clinics in North America and Europe. Exposures: Patch tests to MCI/MI and MI. Main Outcomes and Measures: Prevalence of allergic contact dermatitis to MCI/MI and MI. Results: From 2009 to 2018, participating sites in North America and Europe patch tested a total of 226 161 individuals to MCI/MI and 118 779 to MI. In Europe, positivity to MCI/MI peaked during 2013 and 2014 at 7.6% (ESSCA) and 5.4% (IVDK) before decreasing to 4.4% (ESSCA) and 3.2% (IVDK) during 2017 and 2018. Positive reactions to MI were 5.5% (ESSCA) and 3.4% (IVDK) during 2017 and 2018. In North America, the frequency of positivity to MCI/MI increased steadily through the study period, reaching 10.8% for MCI/MI during 2017 and 2018. Positive reactions to MI were 15.0% during 2017 and 2018. Conclusions and Relevance: The study results suggest that in contrast to the continued increase in North America, isothiazolinone allergy is decreasing in Europe. This trend may coincide with earlier and more stringent government regulation of MI in Europe. |
| المشرفين على المادة: | DEL7T5QRPN (5-chloro-2-methyl-4-isothiazolin-3-one) 229D0E1QFA (2-methyl-4-isothiazolin-3-one) |
| تواريخ الأحداث: | Date Created: 20230118 Date Completed: 20230320 Latest Revision: 20240119 |
| رمز التحديث: | 20240119 |
| مُعرف محوري في PubMed: | PMC9857829 |
| DOI: | 10.1001/jamadermatol.2022.5991 |
| PMID: | 36652228 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 2168-6084 |
|---|---|
| DOI: | 10.1001/jamadermatol.2022.5991 |